Considerations for the Management of Women with Breast Cancer during the COVID-19 PandemicSource of Funding Nil.
Outcomes in cancer patients are strongly influenced by timeliness and quality of multidisciplinary interventions. The COVID-19 pandemic has led to severe disruption in cancer care in many countries. This has necessitated several changes in clinical care and workflow, including resource allocation, team segregation and deferment of many elective procedures. Several international oncological societies have proposed guidelines for the care of patients afflicted with breast cancer during the pandemic with a view to optimize resource allocation and maximize risk versus benefit for the individual and society. Clinicians may utilize these recommendations to adapt patient care, based on the current availability of resources and severity of the COVID-19 pandemic in each region. This article discusses the guidelines for care of patients afflicted with breast cancer during the pandemic.
29 September 2020 (online)
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Yu J, Ouyang W, Chua MLK, et al. SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan. JAMA Oncol 2020;(e-pub ahead of print). doi: https://dx.doi.org/10.1001%2Fjamaoncol.2020.0980
- 2 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21 (03) 335-337
- 3 Ueda M, Martins R, Hendrie PC. et al. Managing cancer care during COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw 2020; 18 (04) 1-4
- 4 Gasparri ML, Gentilini OD, Lueftner D, Kuehn T, Kaidar-Person O, Poortmans P. Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST). Breast 2020; 52: 110-115 DOI: 10.1016/j.breast.2020.05.006.
- 5 Cancer Care Ontario. Identify priority problems and goals to improve the model of care. Available at: https://www.cancercareontario.ca/en/system/files_force/derivative/PEPPAToolkit_Step4.pdf?download=1. Accessed, June 23 2020
- 6 Cherny NI, Dafni U, Bogaerts J. et al. ESMO-Magnitude of clinical benefit scale version 1.1. Ann Oncol 2017; 28 (10) 2340-2366
- 7 Coles CE, Aristei C, Bliss J. et al. International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic. Clin Oncol (R Coll Radiol) 2020; 32 (05) 279-281
- 8 Macchine D. Clinical guide for the management of cancer patients during the coronavirus pandemic. 2020; Available at: https://www.uhb.nhs.uk/coronavirus-staff/downloads/pdf/CoronavirusCancerManagement.pdf. Accessed June 23, 2020
- 9 National Institute for Health and Care Excellence. NICE COVID-19 rapid guideline: delivery of systemic anticancer treatments. Available at: https://www.nice.org.uk/guidance/ng161. Accessed August 21, 2020
- 10 American College of Surgeons. COVID-19 guidelines for triage of breast cancer patients. Available at: https://www.facs.org/covid-19/clinical-guidance/elective-case/breast-cancer. Accessed August 21, 2020
- 11 de Azambuja E, Trapani D, Loibl S. et al. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer. ESMO Open 2020; 5 (Suppl. 03) e000793
- 12 Dietz JR, Moran MS, Isakoff SJ. et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat 2020; 181 (03) 487-497
- 13 Association of Breast Surgery. Association of breast surgery statement, 27th April 2020. Available at: https://associationofbreastsurgery.org.uk/media/252026/abs-statement-270420.pdf. Accessed August 21, 2020
- 14 Nishiura H, Kobayashi T, Miyama T. et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020; 94: 154-155
- 15 van Maaren MC, Bretveld RW, Jobsen JJ. et al. The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival. Br J Cancer 2017; 117 (02) 179-188
- 16 Agrawal RK, Alhasso A, Barrett-Lee PJ. et al. FAST Trialists group. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol 2011; 100 (01) 93-100
- 17 Murray Brunt A, Haviland JS, Wheatley DA. et al. FAST-Forward Trial Management Group. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 2020; 395 (10237) 1613-1626
- 18 Earl HM, Hiller L, Vallier AL. et al. PERSEPHONE Steering Committee and Trial Investigators. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019; 393 (10191) 2599-2612
- 19 Dowsett M, Ellis MJ, Dixon JM. et al. Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. NPJ Breast Cancer 2020; (e-pub ahead of print) DOI: 10.1038/s41523-020-0168-9.